Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 19, Issue 11, Pages 681-697Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41571-022-00685-3
Keywords
-
Categories
Ask authors/readers for more resources
Despite the rise of novel targeted agents and immunotherapies, chemotherapy remains the primary treatment for most human malignancies. However, chemotherapy-associated adverse events (CAAEs) have a significant impact on patients' physical, emotional, and social well-being. Efforts to identify and summarize management approaches for CAAEs are currently limited. This review focuses on the most common acute CAAEs that affect survival, quality of life, function, and continuation of optimal therapy, providing insights into their underlying causes, evidence-based treatments, prevention strategies, and management recommendations.
Despite the enthusiasm surrounding novel targeted agents and immunotherapies, chemotherapy remains the mainstay treatment for most human malignancies, either alone or in combination. Yet, the burden of chemotherapy-associated adverse events (CAAEs) remains high and, importantly, is associated with considerable morbidity, mortality and costs that affect patients across multiple dimensions, including physical, emotional and social functioning. CAAEs can directly affect patient outcomes and indirectly increase the risk of cancer recurrence by compromising treatment intensity and continuity. Systematic efforts to identify and critically summarize the evidence on management approaches for CAAEs remain limited. Herein, we review the most common acute CAAEs having a major effect on survival, quality of life, function and/or continuation of optimal therapy. We focus on selected acute toxicities that occur during treatment, summarizing their underlying pathophysiology, multifactorial aetiologies, evidenced-based treatments, prevention strategies and management recommendations. We also summarize the available evidence on risk factors, validated risk assessment tools and other efforts to optimize symptom control in patients most likely to benefit in order to personalize the prevention and treatment of acute CAAEs. Finally, we discuss innovative symptom monitoring and supportive care interventions that are under development to further improve the outcomes of patients with cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available